Sequential Stem Cell-Kidney Transplantation in Schimke Immuno-osseous Dysplasia.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 35704481.
- Also identified by DOI 10.1056/NEJMoa2117028 and PMC identifier 10545450.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lifelong immunosuppression is required for allograft survival after kidney transplantation but may not ultimately prevent allograft loss resulting from chronic rejection. We developed an approach that attempts to abrogate immune rejection and the need for post-transplantation immunosuppression in three patients with Schimke immuno-osseous dysplasia who had both T-cell immunodeficiency and renal failure. Each patient received sequential transplants of αβ T-cell-depleted and CD19 B-cell-depleted haploidentical hematopoietic stem cells and a kidney from the same donor. Full donor hematopoietic chimerism and functional ex vivo T-cell tolerance was achieved, and the patients continued to have normal renal function without immunosuppression at 22 to 34 months after kidney transplantation. (Funded by the Kruzn for a Kure Foundation.).
Medical subject headings
- Hematopoietic Stem Cell Transplantation
- Immunologic Deficiency Syndromes
- Kidney Transplantation
- Nephrotic Syndrome
- Osteochondrodysplasias
- Primary Immunodeficiency Diseases